Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer

Next Previous
Trial Profile

A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabazitaxel (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CGC
  • Sponsors Sanofi

Most Recent Events

  • 05 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 Apr 2028.
  • 05 Feb 2024 Planned primary completion date changed from 1 Jun 2022 to 1 Apr 2026.
  • 05 Feb 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top